Suppliers ramp up efforts to supply needed primary packaging.

Gearing Up for Vaccine Delivery

How has the COVID-19 pandemic impacted biomanufacturing operations?

SARS-CoV-2 and Biomanufacturing

Topic

Articles

A Phase III trial to evaluate safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S, is enrolling participants on three continents. 

Johnson & Johnson Launches Multi-Country Phase III Trial of Janssen’s COVID-19 Vaccine Candidate

Samsung will offer large-scale commercial manufacturing for drug substance and drug products to support AstraZeneca’s biologics therapeutics capabilities in the Asia-Pacific region.

AstraZeneca and Samsung Biologics to Enter into Long-Term Supply Agreement for Up to $545.6 Million

The collaboration will expand the manufacturing capacity for lenzilumab, a COVID-19 therapeutic candidate, in advance of a potential Emergency Use Authorization in 2020.

Lonza, Humanigen Partner to Expand Manufacturing of Lenzilumab for Potential COVID-19 Therapy

The agreement will Increase global manufacturing capacity for Novavax’s vaccine candidate, NVX-CoV2373, to more than two-billion annualized doses when at full capacity in 2021.

Novavax in COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India

The agreement between the two companies will significantly increase global supply capacity for Lilly's potential COVID-19 treatments.

Lilly and Amgen in Manufacturing Collaboration for COVID-19 Antibody Therapies

The Russian Direct Investment Fund has announced three deals with India, Brazil, and Mexico, for the supply of doses of Sputnik V, a potential COVID-19 vaccine.

Russia Completes Deals with India, Mexico, and Brazil for Sputnik V

The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.

Cytiva Invests $500 Million Over 5 years to Expand Global Capacity

Clinical trials for AZD1222 coronavirus vaccine resume in the UK as per guidance by MHRA.

AZD1222 Clinical Trials Resume in the UK

The investment at its Madison, WI, facility will expand MilliporeSigma’s capacity for high-potent active pharmaceutical ingredient production and allow for continuous flow manufacturing of ADCs.

MilliporeSigma Invests $65 Million to Expand Antibody-Drug Conjugate Manufacturing

The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.

Catalent Invests $130 Million to Expand Gene Therapy Manufacturing Capacity

Cleanroom Equipment and Supplies

Clinical Trial Materials

Facility Design and Engineering